BioXmark

BioXmark is a novel, injectable liquid fiducial marker designed to enhance target visibility on imaging for high-precision image-guided radiotherapy (IGRT) and proton-beam therapy. It is composed of sucrose acetate isobutyrate (SAIB), an iodinated SAIB derivative (x-SAIB), and ethanol. Upon injection, the ethanol diffuses out within 1–2 hours, resulting in the formation of a hydrophobic semisolid gel-like marker at the site. The proprietary iodine-based contrast agent ensures radiopacity and visibility across multiple imaging modalities including X-ray, CT, CBCT, ultrasound, and MRI. BioXmark markers are non-metallic with low artifact levels and minimal dose perturbation—making them compatible with both photon and proton therapies. The product enables customizable implantation of multiple markers in a single procedure using standard equipment such as thin needles or flexible scopes. It remains stable at the injection site for months without significant migration or adverse events reported in clinical studies[2][3][4][5][6]. BioXmark is indicated for use to radiographically mark soft tissue—including lung, bladder, lymph nodes—in adult patients undergoing radiation therapy[2][4]. Developed by Nanovi (Lyngby, Denmark), it has received De Novo clearance from the US FDA.

Brand names

BioXmark

Other names

bioxmarkBioXmark liquid fiducial marker